| P2093 | author name string | Yutaka Yasui | |
| | Christopher J Kemp | |
| | Karen S Kelly-Spratt | |
| | Kay E Gurley | |
| P2860 | cites work | The Hallmarks of Cancer | Q221226 |
| | Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53 | Q22009955 |
| | Mdm2 promotes the rapid degradation of p53 | Q24322597 |
| | Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a | Q24324559 |
| | p53-independent functions of the p19(ARF) tumor suppressor | Q24600863 |
| | Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53 | Q24672736 |
| | Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells | Q27860599 |
| | Regulation of p53 stability by Mdm2 | Q27860744 |
| | Tumor suppression by Ink4a-Arf: progress and puzzles | Q28207959 |
| | The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53 | Q28266637 |
| | Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest | Q28270478 |
| | The complexity of p53 modulation: emerging patterns from divergent signals | Q28284854 |
| | Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. | Q28590239 |
| | Longitudinal data analysis for discrete and continuous outcomes | Q29547235 |
| | Live or let die: the cell's response to p53 | Q29547663 |
| | Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours | Q29547697 |
| | ras oncogenes in human cancer: a review | Q29547769 |
| | Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization | Q29614701 |
| | A causal role for E-cadherin in the transition from adenoma to carcinoma | Q29616122 |
| | p53: puzzle and paradigm | Q29618407 |
| | Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF | Q29619663 |
| | Nucleolar Arf sequesters Mdm2 and activates p53 | Q29620244 |
| | p53 induction and apoptosis in response to radio- and chemotherapy in vivo is tumor-type-dependent | Q31983459 |
| | The cellular response to p53: the decision between life and death | Q33771774 |
| | The relevance of oncogenes as prognostic markers in cervical cancer | Q78336633 |
| | Amplification of wild-type K-ras promotes growth of head and neck squamous cell carcinoma | Q78710253 |
| | Cooperativity of p19ARF, Mdm2, and p53 in murine tumorigenesis | Q79227607 |
| | The ARF/p53 pathway | Q33840421 |
| | Understanding Ras: 'it ain't over 'til it's over'. | Q33877218 |
| | Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. | Q33888123 |
| | A genome-wide survey of RAS transformation targets | Q33888438 |
| | The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. | Q33889383 |
| | Transcriptional regulation of cell invasion: AP-1 regulation of a multigenic invasion programme | Q34013797 |
| | Cellular senescence: mitotic clock or culture shock? | Q34019131 |
| | The Arf tumor suppressor gene promotes hyaloid vascular regression during mouse eye development | Q34020783 |
| | Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis | Q34162269 |
| | Oncogenic ras and p53 cooperate to induce cellular senescence | Q34279104 |
| | AP-1 in mouse development and tumorigenesis | Q34279346 |
| | Database of p53 gene somatic mutations in human tumors and cell lines | Q34868968 |
| | Promising molecular targets for cancer prevention: AP-1, NF-kappa B and Pdcd4. | Q35043768 |
| | E1A signaling to p53 involves the p19(ARF) tumor suppressor | Q35206764 |
| | Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis | Q35208288 |
| | INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. | Q35208402 |
| | Multistage carcinogenesis in mouse skin | Q35853804 |
| | Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation | Q35861554 |
| | Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways | Q35964906 |
| | Signaling pathways in Ras-mediated tumorigenicity and metastasis. | Q36219180 |
| | Oncogene amplification during tumorigenesis of established rat fibroblasts reversibly transformed by activated human ras oncogenes | Q36917447 |
| | p38 kinase is a key signaling molecule for H-Ras-induced cell motility and invasive phenotype in human breast epithelial cells | Q38519488 |
| | Nucleolar Arf tumor suppressor inhibits ribosomal RNA processing | Q40666241 |
| | The pathogenesis of squamous cell cancer: lessons learned from studies of skin carcinogenesis--thirty-third G. H. A. Clowes Memorial Award Lecture. | Q40720266 |
| | Activated ras regulates the proliferation/apoptosis balance and early survival of developing micrometastases | Q40752491 |
| | Molecular mechanisms leading to cell junction (cadherin) deficiency in invasive carcinomas | Q40859766 |
| | TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells | Q41164260 |
| | Mediation of c-Myc-induced apoptosis by p53. | Q41441186 |
| | Predisposition to neoplastic transformation caused by gene replacement of H-ras1. | Q41548182 |
| | Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis | Q41563751 |
| | Alterations of the p53 tumor suppressor gene during mouse skin tumor progression | Q41652802 |
| | Loss of heterozygosity and mutational alterations of the p53 gene in skin tumours of interspecific hybrid mice | Q41654720 |
| | Genetic changes in skin tumor progression: correlation between presence of a mutant ras gene and loss of heterozygosity on mouse chromosome 7. | Q41734552 |
| | Arf induces p53-dependent and -independent antiproliferative genes. | Q42804606 |
| | Progression of squamous carcinoma cells to spindle carcinomas of mouse skin is associated with an imbalance of H-ras alleles on chromosome 7 | Q42808827 |
| | Oncogenic Ras downregulates Rac activity, which leads to increased Rho activity and epithelial-mesenchymal transition | Q42919170 |
| | Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. | Q43918911 |
| | Primary rat embryo cells transformed by one or two oncogenes show different metastatic potentials | Q44653161 |
| | A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis. | Q45887002 |
| | NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. | Q45982548 |
| | CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis | Q46492957 |
| | Tumor spectrum in ARF-deficient mice. | Q53423902 |
| | Rho family proteins and Ras transformation: the RHOad less traveled gets congested. | Q53429986 |
| | Increasing complexity of Ras signaling. | Q53429989 |
| | Paradoxical tumor inhibitory effect of p53 loss in transgenic mice expressing epidermal-targeted v-rasHa, v-fos, or human transforming growth factor alpha. | Q53451031 |
| | c-fos is required for malignant progression of skin tumors. | Q53461261 |
| | Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. | Q53478233 |
| | Metastasis is driven by sequential elevation of H-ras and Smad2 levels. | Q54297451 |
| | The p16INK4a/CDKN2A tumor suppressor and its relatives. | Q54317457 |
| | A cellular oncogene (c-Ki-ras) is amplified, overexpressed and located within karyotypic abnormalities in mouse adrenocortical tumour cells | Q57382481 |
| | p19ARF links the tumour suppressor p53 to Ras | Q57562848 |
| | p53- and Mdm2-Independent Repression of NF-κB Transactivation by the ARF Tumor Suppressor | Q58287158 |
| | A deadly inheritance | Q59053969 |
| | Expression of p21 ras oncoproteins in human cancers | Q68858371 |
| | Alterations of myc, myb, and rasHa proto-oncogenes in cancers are frequent and show clinical correlation | Q69991918 |
| | Expression pattern of the cell adhesion molecules. E-cadherin, P-cadherin and alpha 6 beta 4 intergrin is altered in pre-malignant skin tumors of p53-deficient mice | Q70913851 |
| | Rapid allelotype analysis of p53 knockout mice | Q72402908 |
| | Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression | Q77640444 |
| | Human tumor suppressor ARF impedes S-phase progression independent of p53 | Q77678795 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | E242 | |
| P577 | publication date | 2004-08-01 | |
| P1433 | published in | PLOS Biology | Q1771695 |
| P1476 | title | p19Arf suppresses growth, progression, and metastasis of Hras-driven carcinomas through p53-dependent and -independent pathways | |
| P478 | volume | 2 | |